Pfizer Inc. (PFE) — Estimates & Forecasts
Proprietary EPS, revenue & margin forecasts — FY+1 to FY+4
Popular:
Proprietary EPS, revenue & margin forecasts — FY+1 to FY+4
| Metric | 2023 | 2024 | 2025 | 2026E | 2027E | 2028E | 2029E |
|---|---|---|---|---|---|---|---|
| Net Income | $2.1B | $8.0B | $7.8B | $12.2B | $10.8B | $7.4B | $7.6B |
| EPS (Diluted) | $0.37 | $1.41 | $1.36 | $2.14 | $1.91 | $1.31 | $1.34 |
| YoY Growth | — | +276.0% | -3.1% | +56.4% | -11.2% | -31.6% | +2.3% |
| Net Margin | 3.6% | 12.6% | 12.4% | 20.0% | 18.4% | 12.6% | 12.6% |
| Metric | 2025A | 2026E | 2027E | 2028E | 2029E |
|---|---|---|---|---|---|
| Revenue | $62.6B | $60.8B | $58.5B | $58.7B | $60.0B |
| Net Income | $7.8B | $12.2B | $10.8B | $7.4B | $7.6B |
| EPS (Diluted) | $1.36 | $2.14 | $1.91 | $1.31 | $1.34 |
| Free Cash Flow | — | $8.6B | $8.3B | $8.3B | $8.5B |
Forecast is usable, but expect normal estimate drift around earnings and macro events.
Pfizer Inc.'s projected EPS for the next fiscal year is $2.14. This estimate blends our quantitative model with Wall Street analyst consensus and carries a confidence score of 57/100. The model factors in revenue trajectory, margin path, and share buyback trends to arrive at this figure.
Our scenario-based model produces three price targets for Pfizer Inc.: Bear case $13, Base case $39, and Bull case $67. These targets are derived by applying the median historical P/E ratio to forward EPS estimates under each growth scenario. They are not buy/sell recommendations.
Pfizer Inc.'s projected revenue growth for the next fiscal year is -2.9%, reaching approximately $60.8B in total revenue. Growth estimates are probability-weighted and blend analyst consensus with our CAGR extrapolation model. Outer years (FY+3, FY+4) fade toward industry median growth rates.
Accuracy depends on several measurable factors. Our model confidence score of 57/100 is computed from revenue predictability (25% weight), margin stability (20%), historical earnings beat rate (20%), data depth (15%), analyst coverage (10%), and model-consensus agreement (10%). Contracting margins add uncertainty to forward projections. No forecast model is perfect — always cross-reference with your own analysis.
Pfizer Inc.'s forward operating margin is estimated at 24.5% for the next fiscal year. The margin trend is currently "contracting". Our model tracks margin mean-reversion patterns and adjusts for sector-specific cost dynamics. Operating leverage is a key driver of EPS growth beyond top-line revenue expansion.
The v2 model uses a multi-step process: (1) Revenue is projected via blended CAGR with probability weighting, (2) Operating and net margins follow a mean-reversion path calibrated to sector norms, (3) EPS is derived from net income divided by projected diluted shares (accounting for buyback trends), (4) For FY+1 and FY+2, estimates are blended with analyst consensus based on coverage depth, (5) Price targets apply median historical P/E to forward EPS under bear/base/bull growth scenarios. All inputs are from public filings and third-party data providers.
The bear case ($13) assumes P25 revenue growth, worst-case margins, and multiple compression. Key risks include: unexpected margin contraction, revenue deceleration below model floor, regulatory headwinds, macro deterioration, or competitive disruption. A confidence score below 60 suggests higher estimate volatility. Always size positions according to the full scenario range, not just the base case.
Our model is below Wall Street consensus with a 27.5% gap. For FY+1, analyst estimates blend with our model at 50% analyst weight. By FY+3 and FY+4, estimates are purely model-driven as analyst coverage thins out at longer horizons.